News
Curasight A/S ("Curasight" or "the Company") (CPH: CURAS), a clinical stage radiopharmaceuticals company, today announced the European Medicines Agency (EMA) has approved the company's clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results